Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age16+
SponsorUniversity College, London

About this trial

People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum sample. This means they have bacteriologically unconfirmed TB. These individuals often have minimal or no symptoms and face uncertainty in clinical management-either receiving full 24-weeks TB treatment or often being discharged without treatment, risking loss to follow-up.

The RADIO-TB trial aims to address the following main questions in relation to people with bacteriologically unconfirmed TB.

1. What is the risk of progression if treatment is not immediately started but there is close and careful follow-up over 78 weeks? 2. If treatment is started immediately what is the shortest duration of TB treatment that is as effective as the standard 24-week TB treatment? 3. Are there better tests to confirm TB than the current routinely used, sputum-based tests? 4. What is the cost effectiveness of different treatment strategies and what might the impact on transmission be within communities?

Participants in the trial will be randomized into six groups: five receiving immediate standard TB treatment of varying durations (8 to 24 weeks), and one receiving deferred treatment with close monitoring. Deferred treatment will be initiated only if clinical deterioration occurs or TB is later confirmed. Participants will be closely followed for 78 weeks with at least 11 clinic visits.

Eligibility criteria

Qualifiers

Aged ≥16 years old on day of randomisation

≥25kg in weight on day of randomisation

Participation in community or facility-based active case finding for TB by CXR

Digital CXR with Computer Aided Detection software score above threshold for sputum investigation for Mtb according to local guidance ≤21 days prior to randomisation

Disqualifiers

Sputum sample from active case finding or screening confirmed as positive for Mtb by WHO approved rapid molecular test for Mtb

Previous history of pulmonary TB

TB preventive therapy taken within the last 6 months

>1 dose of treatment with anti-tuberculous activity taken in the 21 days prior to randomisation

Trial design

Treatments tested in this trial

  • Isoniazid (H)
  • Rifampicin (R)
  • Pyrazinamide (Z)
  • Ethambutol (E)

Treatment groups

784 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators

University College, London

Lead sponsor

National University of Medical Sciences, Pakistan

Collaborator

Aurum Institute

Collaborator

Biomedical Research and Training Institute, Zimbabwe

Collaborator

Foundation for Innovative New Diagnostics, Switzerland

Collaborator

KTH Royal Institute of Technology

Collaborator

London School of Hygiene and Tropical Medicine

Collaborator

Wits Health Consortium (Pty) Ltd

Collaborator